跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 276 条关于
“Chengdu Kanghong”
全部
276
临床试验
56
药物
141
机构
37
资讯
42
去年
Dual-Payload ADCs Enter Clinical Testing as Innovent and Chengdu Kanghong Pioneer Next-Generation Cancer Therapeutics
7个月前
World's First Dual-Payload ADC KH815 Enters Clinical Trials with BioDlink Manufacturing Support
8年前
Sanofi Establishes €66 Million Global R&D Hub in Chengdu, Expanding China Research Footprint
去年
WuXi Biologics Breaks Ground on China's First Dual-Chamber Lyophilization Manufacturing Site in Chengdu
去年
Chengdu UCELLO Biotech's UC101 Becomes First Allogeneic Universal CAR-T Therapy to Receive FDA IND Approval
去年
Regulatory Setbacks for PTC's Translarna, Eisai/Biogen's Leqembi; Novartis Licenses Cancer Drug from Chengdu Baiyu
4个月前
KH607 Meets Primary Endpoint in Phase 2b Trial for Major Depressive Disorder
11个月前
Biokin Pharmaceutical Receives NMPA Approval for First-in-Class Radiopharmaceutical [177Lu]-BL-ARC001
5个月前
Chinese CDMO Facilities Achieve Major Manufacturing Milestones as Biologics Production Capacity Expands
去年
WuXi Biologics Partners with Virogen to Advance First-in-Class Anti-CD3 Immunotoxin VG712 Toward Commercial Manufacturing
第 1 页,共 5 页
上一页
下一页